YX0798 shows the potential for combined treatment with other agents. (A) In JeKo-1, JeKo BTK KD, and Z138 cells, a combinational drug screen for YX0798 with a list of agents that are FDA approved or under clinical investigation. The y-axis on the right shows the concentration of YX0798 (nanomolar). The color coding for drug efficacy is shown in the legend. (B) In JeKo-1 cells, YX0798 decreased cell viability and (C) increased apoptosis when used in combination with ibrutinib, zanubrutinib, pirtobrutinib, NX-2127, safimaltib, or AZD4320. (D) Western blots show YX0798 enhanced the cleavage of PARP and caspase-3 when combined with ibrutinib, zanubrutinib, pirtobrutinib, NX-2127, safimaltib, or AZD4320. (E) YX0798 decreased cell viability when used in combination with PBN or VEN in primary samples obtained from a PBN-resistant patient. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. ns, not significant; VEN, venetoclax.
Figure 7.

YX0798 shows the potential for combined treatment with other agents. (A) In JeKo-1, JeKo BTK KD, and Z138 cells, a combinational drug screen for YX0798 with a list of agents that are FDA approved or under clinical investigation. The y-axis on the right shows the concentration of YX0798 (nanomolar). The color coding for drug efficacy is shown in the legend. (B) In JeKo-1 cells, YX0798 decreased cell viability and (C) increased apoptosis when used in combination with ibrutinib, zanubrutinib, pirtobrutinib, NX-2127, safimaltib, or AZD4320. (D) Western blots show YX0798 enhanced the cleavage of PARP and caspase-3 when combined with ibrutinib, zanubrutinib, pirtobrutinib, NX-2127, safimaltib, or AZD4320. (E) YX0798 decreased cell viability when used in combination with PBN or VEN in primary samples obtained from a PBN-resistant patient. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. ns, not significant; VEN, venetoclax.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal